Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HER2-positive Gastric Cancer: early-phase trial registry
4 of 7 indexed HER2-positive Gastric Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
HER2-positive Gastric Cancer: 7 US clinical trials tracked, 4 recruiting.
HER2-positive Gastric Cancer is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Pieris Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition her2-positive-gastric-cancer
OPEN 4 | RECR 57% | LATE 2 | EARLY 5 | RANK #2497 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
HER2-positive Gastric Cancer lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HER2-positive Gastric Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HER2-positive Gastric Cancer is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HER2-positive Gastric Cancer research.
Pieris Pharmaceuticals accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical HER2-positive Gastric Cancer enrolment sits around 162 participants.
Median target enrolment is 162 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.
-
HER2-positive Gastric Cancer research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
NCT06764875
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
NCT06532006
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Mersana Therapeutics
NCT05514717
HER-2 B Cell Peptide Vaccine
Pravin T.P Kaumaya
NCT06414733
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
NCT06328738
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Pieris Pharmaceuticals
NCT05190445
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals
NCT03650348
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on HER2-positive Gastric Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HER2-positive Gastric Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HER2-positive Gastric Cancer page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 HER2-positive Gastric Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pieris Pharmaceuticals sponsors the most HER2-positive Gastric Cancer trials on record, review their full trial history before evaluating a specific study. See Pieris Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HER2-positive Gastric Cancer condition card totals 7 registered trials; most-linked intervention Trastuzumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.